SLEEP DISORDERS MARKET ANALYSIS 2008-2018

114 page report published Mar 25, 2008

Price $3,267.00, add to your cart

This report is also available for purchase on a per-page basis.

Report Overview

Purchase by Section

Search Inside

About TF Market Research

...#.#Aim, Scope, and Format Of This Report #.#Introduction to Sleep Disorders #.#Overview of Chapter #.#Introduction to Insomnia #.#Discovery of Barbiturates #.#Market Entry for Non-Barbiturates #.#Arrival of Benzodiazepines #.#Non-benzodiazepines the Revolutionary Compound...

Source:

VISIONGAIN

Geographic Regions:

ENGLAND , EUROPE , LONDON [ENGLAND] , SOUTHEAST ENGLAND REGION , UNITED KINGDOM , WESTERN EUROPE

Industry:

HEALTH CARE

Non-Billable Page Numbers:

1;2;3;4;5;6;7;8;9;10;11;12;112;113;114

Format:

PDF

Sections
	Title	Starting Page	Number of Pages
	Disclosure	1	1
	1 Executive Summary: Pharmaceutical Treatment of Sleep Disorders 2008- 2018	13	1
	1.1 Current Prospects for the Sleep Disorders Market	13	1
	1.1.1 Market Growth Estimate	14	1
	1.1.2 Generic Pharmaceutical Market	14	1
	1.1.3 Market Expansion	14	2
	1.1.4 Market Demand for Short Elimination Half-Life	15	2
	1.1.5 Medications Targeting M1 and M2 Receptors	16	1
	1.1.6 Medications Targeting 5HT2A Receptors	16	1
	1.1.7 Product Label Extension Activities	16	2
	1.1.8 Effect of Direct-To-Consumer (DTC) Advertising	17	1
	1.1.9 Safety Measures for Online Consumers	17	1
	1.2 Aim, Scope, and Format of This Report	18	1
	2 Introduction to Sleep Disorders and their Pharmaceutical Treatment	19	1
	2.1 Introduction to Sleep Disorders	19	1
	2.2 Overview of Chapter	19	1
	2.3 Introduction to Insomnia	20	1
	2.4 Discovery of Barbiturates	20	2
	2.5 Market Entry for Non-Barbiturates	21	2
	2.6 Arrival of Benzodiazepines	22	1
	2.7 Non-Benzodiazepines the Revolutionary Compound	22	3
	2.7.1 Prescription Medicines and OTCs	24	1
	2.8 Pharmacodynamics of Hypnotics	24	2
	2.9 New Scope for Treating Insomnia	25	1
	2.10 Many Forms of Sleep Disturbances	25	2
	2.10.1 Sleep Deprivation	26	1
	2.11 Shift Workers Sleep Disorder (SWSD)	26	2
	2.11.1 Melatonin	27	1
	2.11.2 Valerian	27	2
	2.12 Treatment for insomnia in Depression	28	1
	2.13 Restless Legs Syndrome	29	1
	2.13.1 Off-label Prescription for Restless Legs Syndrome	29	2
	2.14 Other Medical Conditions	30	1
	2.15 Narcolepsy	31	1
	2.15.1 Xyrem for Cataplexy	32	1
	2.15.2 Orphan Disease Status	32	2
	2.15.3 Other Medications for Cataplexy	33	1
	2.16 Obstructive Sleep Apnoea / Hypopnea Syndrome (OSAHS)	33	2
	2.17 Insomnia-A Common Disease	34	2
	2.19 Patient Identification Rate	36	1
	3. Analysis of Current Market	39	1
	3.1 Market Share for World Insomnia Market	39	1
	3.2 Market Dominance Continues for Ambien	45	3
	3.3 Lunesta as Ambien's Contender	47	2
	3.4 Sonata Continues to Form Niche Market	49	2
	3.5 Imovane / Amoban Loses Market Share for Insomnia Treatment	50	2
	3.6 Benzodiazepines Survived as a Low-Priced Sleep Aid	51	2
	3.6.1 Lendormin (brotizolam)	52	1
	3.6.2 Halcion (triazolam)	53	1
	3.6.3 Noctamid (Lormetazepam)	53	1
	3.6.4 Doral (quazepam)	53	1
	3.6.5 Dalmane (flurazepam)	53	1
	3.6.6 Rohypnol (flunitrazepam)	53	1
	3.6.7 Restoril (temazepam)	54	1
	3.6.8 Eurodin or ProSom or Esilgan (estazolam)	54	1
	3.6.9 Rhythmy (rilmazafone)	54	1
	3.6.10 Valium (diazepam)	54	1
	3.7 Rozerem Market Up-and-Coming	54	2
	4 World Insomnia Market by Regions	56	1
	4.1 US has the Highest Market Share for Insomnia Treatments	56	3
	4.2 Europe as a Significant Market for Insomnia	62	2
	4.3 The Japanese Market is Expanding	71	1
	5 Market Developments for Narcolepsy, Obstructive Sleep Apnoea / Hypopnea Syndrome, Shift Work Sleep Disorder and Restless Le	74	1
	5.1 Provigil Wins Label Extension	74	4
	5.2 Adrafinil is a Isomer of Provigil	77	1
	5.3 Ritalin/ Ritalin SR	77	2
	5.4 Concerta is an Extension Version of Ritalin	78	1
	5.5 Adderall as Stimulant	78	1
	5.6 Xyrem for Cataplexy and Excessive Daytime Sleepiness (EDS)	79	1
	5.7 Recent FDA Activities for Restless Legs Syndrome	79	1
	6 Products in Development for Sleep Disorders	81	1
	6.1 FDA Approves Generic Ambien	81	1
	6.2 Circadin a Prolonged-Release Melatonin	82	1
	6.3 GHB Analogue Generally Regarded as Safe	82	1
	6.4 Clinical Trial Product List	83	1
	6.5 Indiplon for Insomnia in Pre-Registration Stage	84	1
	6.6 Caraco's Prospect in Narcolepsy Market	84	1
	6.7 Lundbeck faces Setback in Insomnia Market	84	1
	6.8 Phase III trial begins on Posidorm for Insomnia	85	1
	6.9 Hope for Physiological Sleep with Almorexant	85	1
	6.10 5HT2A Antagonist for Insomnia	85	2
	6.11 Agonist at the Serotonin 5-HT1A Receptor	87	1
	6.12 VEC-162 has Superior Sleep Maintenance to Rozerem	87	1
	6.13 Zolpidem as Oral Spray	87	1
	6.14 Cephalon Adds Nuvigil Alongside Provigil	87	1
	6.15 Dopamine Patch	87	2
	6.16 Transported Prodrug of Gabapentin	88	1
	7 Recommendation for Ideal Pharmaceutical Treatment for Sleep Disorders	89	1
	7.1 Firsthand Interview for Expert Opinion (First Interview)	89	1
	7.1.2 Prospect for Sleep Disorders Market	89	1
	7.1.3 Prospect for Generic Market	89	2
	7.1.4 Product Line Extension	90	1
	7.1.5 Prospect for Niche Market	90	2
	7.1.6 Future of Benzodiazepines Market	91	1
	7.1.7 Future of Controlled Drug Market	91	1
	7.1.8 Effect of Direct-to-Consumer Market	91	2
	7.1.9 Future of Non-Hypnotics Medications	92	1
	7.1.10 Future Medications for Sleep Apnoea	92	1
	7.1.11 Prospect for Hypnotics as OTCs	92	1
	7.1.12 Unmet Needs for Sleep Disorders Market	93	1
	7.2 Firsthand Interview for Expert Opinion (Second Interview)	93	1
	7.2.1 Drug Therapies for the Future	93	2
	7.2.2 Technological Advance in Sleep Disorders Treatment	94	1
	7.2.3 New Effective Sleep Medications	94	2
	7.2.4 Future of Sleep Disorders Market in the Developed Nations	95	1
	7.2.5 Unmet Needs for Sleep Disorders Treatment	95	1
	7.2.6 Favourable Medication for the Coming Decade	96	1
	7.2.7 Side-Effect Profile for Future Drug Development	96	1
	7.2.8 Sleep Disorders Market in Developing Nations	96	2
	8 Market Force and Limitation of Sleep Disorders Market	98	1
	8.1 Table for SWOT Analysis of Sleep Disorders Market	98	1
	8.2 Market Analysis of Products Unapproved for Sleep Disorders by Regulatory Bodies and Niche Market	100	1
	8.2.1. Unapproved Insomnia Medications: Benadryl, Unisom, Tylenol PM, Nytol	100	1
	8.2.3 Purchase of Prescription Medications Online	100	3
	8.3 Drug Safety Issues and Side-Effects of Drugs	102	1
	8.3.1 Hypnotics Are Not Without Side-Effects	102	2
	8.3.2 Labelling to Include Potential Risks	103	2
	8.3.3 Rohypnol and Xyrem have Potential for Abuse	104	1
	8.3.4. Consumer Led Campaign	104	2
	8.4 Unmet needs of Pharmaceutical Treatment for Sleep Disorders	105	1
	8.5Non-product Related Drivers and Restraints	106	1
	8.5.1 National Policies Recommendations	106	1
	8.5.2 National Policies Advising Prescription of Particular Drugs	106	1
	8.5.3 Agreed Guidelines	107	1
	8.5.4 Market Status Quo	107	1
	8.6 Success of Direct-to-Consumer Advertising	107	3
	9. Conclusions	110	1
	9.1 Insomnia Market Will Show High Growth	110	1
	9.2 Other Sleep Disorders Acquire Some Degree of Interest	110	1
	9.3 Life-Cycle Management	111	1
	9.4 New Markets	111	1
	Disclosure	112	1

Enter the keyword(s) which you would like to search for within this document and click "Search"

TF Market Research® reports contain in-depth primary research and statistics, market trends, forecasts, segment analysis and much more from over 100 top consulting, market research and business publishing sources. The service is updated daily.

Price: $3,267.00

$ £ €

Questions about
this research?

Send page to a friend

Return to
Alacra Company Snapshot

More Market Research

Search all our Market Research from one place.

Get FREE Research

Can't Decide?

Purchasing premium research sight unseen can be intimidating. We want you to know what you are getting. Visit our FAQ or ask our Customer Service Team any questions about the report you are considering purchasing.